利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.046 秒)

    Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
    3.
    发明授权
    Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo 有权

    公开(公告)号：US10383847B2

    公开(公告)日：2019-08-20

    申请号：US14250958

    申请日：2014-04-11

    申请人： Dennis M. Brown ,  Ian Nisbet

    发明人： Dennis M. Brown ,  Ian Nisbet

    IPC分类号： A61K31/404 ,  A61K45/06 ,  C07K16/40 ,  C12N15/113 ,  A61K31/7056 ,  A61K39/395 ,  C07D209/34

    摘要： The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutically active agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo. In particular, the therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo, are effective Nek9 inhibitors. The active agent, such as meisoindigo, can act as a Nek9 inhibitor. The active agent can be used together with Nek9 inhibitors or agents that inhibit the expression of Nek9.

    CEPHALOTAXINE ALKALOID COMPOSITIONS AND USES THEREOF
    6.
    发明申请
    CEPHALOTAXINE ALKALOID COMPOSITIONS AND USES THEREOF 审中-公开
    CEPHALOTAXINE ALKALOID组合物及其用途

    公开(公告)号：US20120207855A1

    公开(公告)日：2012-08-16

    申请号：US13336917

    申请日：2011-12-23

    申请人： Dennis M. Brown

    发明人： Dennis M. Brown

    IPC分类号： A61K33/24 ,  A61P35/00 ,  A61K31/55

    CPC分类号： A61K45/06 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/513 ,  A61K31/55 ,  A61K31/70 ,  A61K31/7048 ,  A61K31/7076 ,  A61K33/24 ,  A61K2300/00

    摘要： A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl)butanediocate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes.

    摘要翻译： 描述了一种治疗具有细胞增殖性疾病的宿主的方法，包括使宿主与足以调节所述细胞增殖性疾病的量的头孢噻肟和抗增殖剂接触。 在一些实施方案中，头孢噻肟含有高粱素（头孢噻肟，4-甲基-2-羟基-2-（4-羟基-4-甲基戊基）丁二酸酯）。 本发明的抗增殖剂包括烷化剂，嵌入剂，金属配位络合物，嘧啶核苷，嘌呤核苷，核酸相关酶和蛋白质的抑制剂以及影响结构蛋白和细胞质酶的试剂。

    Formulations and Methods of Administration of Cephalotaxines, Including Homoharringtonine
    7.
    发明申请
    Formulations and Methods of Administration of Cephalotaxines, Including Homoharringtonine 审中-公开
    头孢噻肟的配方和方法，包括Homoharringtonine

    公开(公告)号：US20120058991A1

    公开(公告)日：2012-03-08

    申请号：US13294776

    申请日：2011-11-11

    申请人： Dennis M. Brown

    发明人： Dennis M. Brown

    IPC分类号： A61K31/55 ,  A61P35/00 ,  A61P35/02 ,  C07D491/147

    CPC分类号： A61K36/13 ,  A61K31/55 ,  C07D419/14 ,  C07D491/20

    摘要： The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.

    摘要翻译： 本发明涉及用于治疗患有头孢噻肟的患者的组合物和方法，例如高质蛋白胨。 本发明还涉及改善用于治疗癌症和其它异常细胞疾病的同型异亮氨酸的纯度，制造方法，制剂和给药。 本发明还提供了抗寄生虫，抗真菌，抗病毒和抗菌处理的方法和组合物。

    Method for managing returns
    8.
    发明授权
    Method for managing returns 有权
    管理退货的方法

    公开(公告)号：US07822651B2

    公开(公告)日：2010-10-26

    申请号：US10612659

    申请日：2003-07-02

    申请人： Delma S. Hume ,  Robert L. Flint ,  Steven L. Guse ,  Robert J. Rachowicz ,  Dennis M. Brown ,  Milo O. Twist ,  Theresa D. Wire

    发明人： Delma S. Hume ,  Robert L. Flint ,  Steven L. Guse ,  Robert J. Rachowicz ,  Dennis M. Brown ,  Milo O. Twist ,  Theresa D. Wire

    IPC分类号： G06F17/60

    CPC分类号： G06Q10/0837 ,  G06Q10/06 ,  G06Q10/087 ,  G06Q30/0601

    摘要： There are many situations where returns are needed to further business or other objectives. For example, in remanufacturing businesses, cores are rebuilt into remanufactured parts that are sold. To sustain remanufacturing, cores must be obtained. One way to assure a supply is to collect a deposit against a core return when a remanufactured part is sold. Tracking of cores and the associated liabilities for the deposits is complex. It is also beneficial to control the liabilities. Provided are systems, methods and steps that enable tracking and other effective management techniques to assure returns and liabilities are managed. In one embodiment, each core and an associated entitlement representative of a liability are tracked. Price changes can be made on core deposits without affecting the ability to control liabilities. The systems, processes and methods lend themselves to computer implementation and use in large businesses.

    摘要翻译： 在许多情况下，需要回报以进一步的业务或其他目标。 例如，在再制造业务中，核心被重建到已经出售的再制造零件中。 为了维持再制造，必须获得核心。 确保供应的一种方法是在再制造零件出售时收取核心回报的存款。 核心跟踪和相关负债的存款是复杂的。 控制负债也是有益的。 提供的系统，方法和步骤能够跟踪和其他有效的管理技术，以确保回报和负债得到管理。 在一个实施例中，跟踪代表责任的每个核心和相关权利。 核心存款可以进行价格变动，而不影响负债的控制能力。 系统，流程和方法适用于大型企业的计算机实现和使用。

    Surgical adhesive material
    10.
    发明授权
    Surgical adhesive material 失效
    手术粘合剂材料

    公开(公告)号：US5290552A

    公开(公告)日：1994-03-01

    申请号：US855921

    申请日：1992-03-23

    申请人： David H. Sierra ,  Edward E. Luck ,  Dennis M. Brown

    发明人： David H. Sierra ,  Edward E. Luck ,  Dennis M. Brown

    IPC分类号： A61L24/00 ,  A61L24/10 ,  A61K35/16 ,  A61K37/547

    CPC分类号： A61L24/102 ,  A61L24/0005 ,  A61L24/0084 ,  Y10S514/801

    摘要： The present invention provides a surgical adhesive comprising, in an aqueous composition, fibrinogen, FXIII, collagen, thrombin, Ca.sup.2+ and optionally, an antifibrinolytic agent. The present adhesive may be formed from the patient's plasma without the use of any added reagents for concentration or isolation of the fibrinogen. Conveniently, the adhesive is formulated as a two-part composition which is mixed together just prior to use.

    摘要翻译： 本发明提供一种手术粘合剂，其在水性组合物中包含纤维蛋白原，FXIII，胶原，凝血酶，Ca 2+和任选的抗纤维蛋白溶解剂。 本发明的粘合剂可以由患者的血浆形成，而不使用用于浓缩或分离纤维蛋白原的任何添加的试剂。 方便地，粘合剂被配制为在使用之前混合在一起的两部分组合物。